Bright Minds Biosciences Initiates PWS Program with BMB-105 Nomination.
ByAinvest
Thursday, Nov 6, 2025 6:36 am ET1min read
DRUG--
Bright Minds Biosciences has initiated its Prader-Willi Syndrome program and nominated BMB-105 as a new clinical candidate. The company will host a webcast to discuss its Phase 2a study, which will assess the efficacy, safety, and tolerability of BMB-101 for treating patients with PWS. Key opinion leaders will participate in the call, highlighting the strong pre-clinical and clinical rationale supporting the potential of BMB 5-HT2C agonists to address both neuropsychiatric symptoms and hyperphagia.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet